Human autoimmune diseases are characterized by chronic, non-remitting inflammation. In the early phase of chronic arthritis auto-reactive T cells initiate a cascade of events that leads to chronic inflammation. Following the initial phase of the disease, other cells such as macrophages and monocytes mainly mediate the ongoing non-specific inflammation. At this later stage, auto reactive T cells presumably do not play an important role in sustaining the chronic inflammation. Mechanisms underlying the perpetuation of this cascade of non-specific inflammation are still poorly understood. As a consequence, treatment of the disease until now has been mainly focused on non-specific suppression of inflammation. In patients with chronic arthritis, such juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) blockade of the tumour necrosis factor alpha pathway has proven to be a very potent treatment option. On the other hand, such treatment is costly and fails to induce a long-lasting remission of the disease. As a consequence long-term treatment with immune suppressive agents is necessary, which increases not only the costs of the treatment but also harbours considerable risk for long-term side effects. Thus, the need for additive and/or alternative strategies is growing. Ideally such alternative treatment should be safe, not expensive and specifically modulate cells that are responsible for the inflammation and/or counter-regulation. Lately, a lot of attention has focused on the role of regulatory T cells for the control of autoimmunity. There are currently two well-characterized types of regulatory T cells, Tr1 cells and CD4^+^CD25^+^T regulatory cells. The CD4^+^CD25^+^T regulatory cells are a heterogeneous group of cells identified by the expression of CD25 and the transcription factor foxP3. We recently showed that these so-called naturally occurring T regulatory cells and regulatory T cells with specificity towards heat shock proteins may play a role in determining disease outcome in JIA \[[@B1],[@B2]\]. Following autologous stem cell transplantation for arthritis T regulatory cell function is restored coinciding with a remission of the arthritis (de Kleer *et al*., submitted). Moreover, oral treatment with a peptide (dnaJP1), derived from heat shock protein dnaJ, restored T regulatory cells in peripheral blood mononuclear cells from patients with RA \[[@B3]\].

Thus, due to insufficient numbers of regulatory T cells, feedback mechanisms fail, resulting in an unrestrained proinflammatory immune response and severe tissue damage in RA and JIA. A lack of a counter-regulatory mechanism based by regulatory T cells is at least in part responsible for the perpetuation of inflammation \[[@B4]\]. Heat shock proteins may be instrumental in restoring the immunological balance and thus contribute to a long-lasting disease remission.
